Craig Devoe

18.9k citations

47 papers · 12.7k indexed · 2 hit papers · h-index 17

Impact in

Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in ⓘ

Oncology 35
- Cancer Immunotherapy and Biomarkers 13
- Pancreatic and Hepatic Oncology Research 8
- HER2/EGFR in Cancer Research 5
- Peptidase Inhibition and Analysis 4
- CAR-T cell therapy research 4
- Cancer Treatment and Pharmacology 3
Transplantation 3

Co-authors: Kenar D. Jhaveri (5 shared papers)Rimda Wanchoo (4 shared papers)Nupur N. Uppal (2 shared papers)Vincent Launay‐Vacher (1 shared paper)Valerie S. Barta (1 shared paper)Gilbert Deray (1 shared paper)Ping Jiang (3 shared papers)Oleg Gladkov (5 shared papers)
Journals: Journal of Clinical Oncology (13 papers)Annals of Oncology (3 papers)Clinical Cancer Research (2 papers)Nature Medicine (2 papers)Biology of Blood and Marrow Transplantation (2 papers)
Partner nations: United States Russia United Kingdom

In The Last Decade

Craig Devoe

45 papers receiving 12.6k citations

Hit Papers

align trajectories log scale

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial 2024 · 124 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 Nature Medicine
2017 American Journal of Nephrology

Peers

Countries citing papers authored by Craig Devoe

Since Specialization

Citations

This map shows the geographic impact of Craig Devoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig Devoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig Devoe more than expected).

Fields of papers citing papers by Craig Devoe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig Devoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig Devoe. The network helps show where Craig Devoe may publish in the future.

Co-authors

The 25 scholars most cited alongside Craig Devoe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Craig Devoe Line = papers co-authored together Craig Devoe links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 47 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review American Journal of Nephrology ·Rimda Wanchoo, Sabine Karam, Nupur N. Uppal, Valerie S. Barta, Gilbert Deray, Craig Devoe, Vincent Launay‐Vacher, Kenar D. Jhaveri, (unknown) Hit paper breakdown →	2017	11620
2	Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer Clinical Cancer Research ·Sunil R. Hingorani, William Proctor Harris, J. Thaddeus Beck, Б. А. Бердов, Stephanie A. Wagner, Eduard M. Pshevlotsky, Sergei Tjulandin, Oleg Gladkov, Randall F. Holcombe, Ronald L. Korn, Natarajan Raghunand, Samuel S. Dychter, Ping Jiang, H. Michael Shepard, Craig Devoe	2016	262
3	Genomic Profiling of Small-Bowel Adenocarcinoma JAMA Oncology ·Alexa B. Schrock, Craig Devoe, Robert R. McWilliams, James Sun, Thomas Aparicio, Philip J. Stephens, Jeffrey S. Ross, Richard H. Wilson, Vincent A. Miller, Siraj M. Ali, Michael J. Overman	2017	141
4	Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial Nature Medicine ·Shubham Pant, Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon Murtaza Kasi, Craig Devoe, Alexis D. Leal, Vincent Chung, Olca Baştürk, Haley VanWyk, Amy Tavares, Lochana M. Seenappa, James Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Eileen M. O’Reilly Hit paper breakdown →	2024	124
5	Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer PubMed ·Nausheen Hakim, Rajvi Patel, Craig Devoe, Muhammad Wasif Saif	2019	75
6	Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours British Journal of Cancer ·Geoffrey I. Shapiro, Robert Wesolowski, Craig Devoe, Simon Lord, John R. Pollard, Bart S. Hendriks, Martin Falk, Iván Díaz-Padilla, Ruth Plummer, Timothy A. Yap	2021	56
7	Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus Clinical Cancer Research ·Alexa B. Schrock, Dean C. Pavlick, Samuel J. Klempner, Jon Chung, Brady Forcier, Allison W. Welsh, Lauren Young, B Leyland-Jones, Rodolfo Bordoni, Richard D. Carvajal, Joseph Chao, Razelle Kurzrock, Jason K. Sicklick, Jeffrey S. Ross, Philip J. Stephens, Craig Devoe, Fadi Braiteh, Siraj M. Ali, Vincent A. Miller	2018	54
8	IQGAP2 functions as a GTP-dependent effector protein in thrombin-induced platelet cytoskeletal reorganization Blood ·Valentina A. Schmidt, L E Scudder, Craig Devoe, André Bernards, Lisa Cupit, Wadie F. Bahou	2003	47
9	LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801) Annals of Oncology ·S. Patel, Megan Othus, Víctor M. Prieto, M.C. Lowe, Elizabeth I. Buchbinder, Yuanbin Chen, John Hyngstrom, Christopher D. Lao, T-G. Truong, Shruti Chandra, Kari Kendra, Craig Devoe, A. Hedge, Ankit Mangla, Elad Sharon, Larissa A. Korde, James J. Moon, Vernon K. Sondak, A. Ribas	2022	31
10	A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. Journal of Clinical Oncology ·Sunil R. Hingorani, William Proctor Harris, J. Thaddeus Beck, Б. А. Бердов, Stephanie A. Wagner, Eduard M. Pshevlotsky, Sergei Tjulandin, Oleg Gladkov, Randall F. Holcombe, Ping Jiang, Daniel C. Maneval, Joy Zhu, Craig Devoe	2013	23
11	Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia Cancer ·Amir T. Fathi, Daniel J. DeAngelo, Kristen E. Stevenson, Jonathan E. Kolitz, Julie Asch, Philip C. Amrein, Eyal C. Attar, David P. Steensma, Martha Wadleigh, Julia Foster, Christine Connolly, Ilene Galinsky, Craig Devoe, Richard M. Stone, Donna Neuberg, Karen K. Ballen	2016	22
12	First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors. Journal of Clinical Oncology ·Shubham Pant, Muhammad Furqan, Raghad Abdul-Karim, Vincent Chung, Craig Devoe, Melissa L. Johnson, Alexis D. Leal, Haeseong Park, Zev A. Wainberg, Esther Welkowsky, Christopher M. Haqq, Eileen M. O’Reilly, Colin D. Weekes	2022	20
13	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma OncoImmunology ·Craig L. Slingluff, Hassane M. Zarour, Hussein A. Tawbi, John M. Kirkwood, Michael A. Postow, Philip Friedlander, Craig Devoe, Elizabeth Gaughan, Ileana S. Mauldin, Walter C. Olson, Kelly T. Smith, Mary Macri, Toni Ricciardi, Aileen Ryan, Ralph Venhaus, Jedd D. Wolchok	2021	20
14	Carfilzomib-related acute kidney injury. PubMed ·Kenar D. Jhaveri, Shailaja Chidella, Jeny Varghese, Lionel U. Mailloux, Craig Devoe	2013	19
15	Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant Rimda Wanchoo, Leonardo V. Riella, Nupur N. Uppal, Carlos López, Vinay Nair, Craig Devoe, Kenar D. Jhaveri	2017	19
16	Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer. Journal of Clinical Oncology ·Sunil R. Hingorani, William Proctor Harris, J. Thaddeus Beck, Б. А. Бердов, Stephanie A. Wagner, Eduard M. Pshevlotsky, Sergei Tjulandin, Oleg Gladkov, Randall F. Holcombe, Ping Jiang, Craig Devoe	2015	18
17	Pretreatment Nutritional Status and Response to Checkpoint Inhibitors in Lung Cancer PubMed ·Chung‐Shien Lee, Craig Devoe, Xinhua Zhu, Joanna Fishbein, Nagashree Seetharamu	2020	18
18	AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer. Journal of Clinical Oncology ·Eileen M. O’Reilly, Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon Murtaza Kasi, Craig Devoe, Alexis D. Leal, Vincent Chung, James Perry, Lochana M. Seenappa, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Shubham Pant	2023	16
19	PEG-asparaginase induced severe hypertriglyceridemia Archives of Endocrinology and Metabolism ·Rodolfo J. Galindo, Justin Yoon, Craig Devoe, Alyson K. Myers	2015	15
20	Abstract CT012: Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792) Cancer Research ·Geoffrey I. Shapiro, Robert Wesolowski, Mark R. Middleton, Craig Devoe, Anastasia Constantinidou, Dionysis Papadatos-Pastos, Marjorie Fricano, Yanqiong Zhang, Sharon Karan, John R. Pollard, Marina S. Penney, Mohammed Asmal, Frank Gary Renshaw, Scott Z. Fields, Timothy A. Yap	2016	12

About Craig Devoe

Craig Devoe is a scholar working on Oncology, Transplantation, Hematology, Genetics and Pathology and Forensic Medicine, having authored 47 papers that have together received 12.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), Pancreatic and Hepatic Oncology Research (8 papers), Immunotherapy and Immune Responses (6 papers), HER2/EGFR in Cancer Research (5 papers), Cancer Genomics and Diagnostics (4 papers), Peptidase Inhibition and Analysis (4 papers), CAR-T cell therapy research (4 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Oncology (10.3k citations), Immunology (4.5k citations), Pulmonary and Respiratory Medicine (3.9k citations), Cancer Research (1.3k citations) and Genetics (534 citations). Craig Devoe has collaborated with scholars based in United States, Russia and United Kingdom. Frequent co-authors include Kenar D. Jhaveri, Rimda Wanchoo, Nupur N. Uppal, Vincent Launay‐Vacher, Valerie S. Barta, Gilbert Deray, Ping Jiang, Oleg Gladkov, Sunil R. Hingorani and William Proctor Harris. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Nature Medicine and Biology of Blood and Marrow Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact